Options pursued to treat addiction

Question of the Day

Should Congress make English the official language of the U.S.?

View results

New treatments for addiction to heroin or narcotic painkillers promise longer-lasting relief that may remove some day-to-day uncertainty of care: A once-a-month shot is now approved and a six-month implant is in the final testing phase.

The main treatment options have long been once-a-day medications — controversial methadone or a tablet named buprenorphine — that act as substitutes for the original drug, to suppress withdrawal and craving without the high.

Skipping a dose risks a relapse, but summoning the daily willpower to stick with treatment is “a formidable task,” said Dr. Nora Volkow, director of the National Institute on Drug Abuse.

Last week, the Food and Drug Administration approved the monthly shot Vivitrol for long-term treatment of opioid addiction — to heroin or such painkillers as morphine, OxyContin and Vicodin.

Vivitrol works differently from methadone or buprenorphine. It blocks the high if a recovering addict slips, and it’s not addictive.

Scientists had tried a daily version of Vivitrol’s ingredient, naltrexone, years ago, but too many patients skipped pills. So Alkermes Inc. created the longer-lasting version first for alcoholism in 2006, and now for opioid addiction. In a study of 250 opioid addicts in Russia, more than half of Vivitrol recipients stuck with therapy for the six-month trial. Even more encouraging, 36 percent stayed completely drug-free, compared with 23 percent who received dummy shots.

Next in the pipeline: A matchstick-size implant that for six months at a time slowly oozes a low dose of buprenorphine into the bloodstream, to subdue cravings. A large study published last week deemed the implant, called Probuphine, promising — just over a third of those patients, too, tested drug-free. Ongoing research partly funded by the government should show next spring if it’s ready for FDA evaluation.

“Opioid addicts are notoriously bad at complying with their medication. They like to take drug holidays. They like to party on the weekend,” said Katherine Beebe of Titan Pharmaceuticals, which is developing the Probuphine implant.

Long-acting options also may help make substance abuse treatment more a part of mainstream medicine.

“To have these medications work effectively, you need to stay on them for long periods of time,” said Dr. Patrick O’Connor of the Yale University School of Medicine.

“We are really struggling to get the public and physicians to think of this more like a standard chronic disease — like diabetes, like cancer, like chronic lung disease — and not apply a special stigma to it.”

About 800,000 people in the U.S. are addicted to heroin, and 1.8 million either abuse or are dependent on opioid painkillers, Dr. Volkow said.

About 45,000 people have used Vivitrol since its approval for alcoholism in 2006; the new approval paves the way for insurance coverage of the $1,100 shot for opioid addiction, too. It occasionally causes serious side effects such as liver damage or injection-site reactions. Also, Dr. Volkow warned that it won’t work for people who need addiction care and pain relief at the same time — they’ll still need buprenorphine.

But Dr. Volkow expects Vivitrol will attract painkiller addicts who have never considered other options, plus people struggling with daily therapy.

T.J. Voller of Westborough, Mass., became addicted to OxyContin after an injury at 23 and moved on to heroin. Two tries of buprenorphine worked only briefly.

“If I didn’t want to take it and wanted to get high, there was nothing to stop me,” said Mr. Voller, 29. He has been on Vivitrol for nearly a year and is back in college. “I get an injection once a month and I don’t have to worry. I’m not saying I don’t have my bad days, but they’re much more manageable.”

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Comments
blog comments powered by Disqus
TWT Video Picks